Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PRN.TO
- Price
- 8.30
- Stock movement up
- +0.09 (1.10%)
- Company name
- Profound Medical Corp
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Medical Devices
- Market cap
- 249.24M
- Ent value
- 225.95M
- Price/Sales
- 31.63
- Price/Book
- 6.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -7.00%
- 1 year return
- -26.22%
- 3 year return
- -10.51%
- 5 year return
- -6.08%
- 10 year return
- -
Last updated: 2025-04-03
DIVIDENDS
PRN.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 31.63 |
| Price to Book | 6.35 |
| EV to Sales | 28.67 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 30.03M |
| EPS (TTM) | -1.13 |
| FCF per share (TTM) | -1.38 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 7.88M |
| Gross profit (TTM) | 4.83M |
| Operating income (TTM) | -14.99M |
| Net income (TTM) | -27.59M |
| EPS (TTM) | -1.13 |
| EPS (1y forward) | -1.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 61.24% |
| Operating margin (TTM) | -190.24% |
| Profit margin (TTM) | -350.14% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.08M |
| Net receivables | 7.16M |
| Total current assets | 48.49M |
| Goodwill | 0.00 |
| Intangible assets | 374.00K |
| Property, plant and equipment | 1.17M |
| Total assets | 50.03M |
| Accounts payable | 2.67M |
| Short/Current long term debt | 6.65M |
| Total current liabilities | 5.63M |
| Total liabilities | 10.79M |
| Shareholder's equity | 39.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -22.80M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -33.74M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -70.32% |
| Return on Assets | -55.15% |
| Return on Invested Capital | -60.69% |
| Cash Return on Invested Capital | -74.22% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.56 |
| Daily high | 8.56 |
| Daily low | 8.30 |
| Daily Volume | 1K |
| All-time high | 35.63 |
| 1y analyst estimate | 25.03 |
| Beta | 0.83 |
| EPS (TTM) | -1.13 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| PRN.TO | S&P500 | |
| Current price drop from All-time high | -76.70% | -8.48% |
| Highest price drop | -87.85% | -56.47% |
| Date of highest drop | 26 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -43.10% | -11.07% |
| Avg time to new high | 61 days | 12 days |
| Max time to new high | 1042 days | 1805 days |
COMPANY DETAILS
Marketcap
249.24M
Marketcap category
Small-cap
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Employees
131
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...
March 25, 2025
Potential Profound Medical Corp. ( TSE:PRN ) shareholders may wish to note that the Chairman of the Board & CEO, Arun...
March 20, 2025
Profound Medical Corp (PROF) reports a 108% revenue growth and a significant reduction in net loss, while navigating challenges in site expansion and reimbursement strategies.
March 7, 2025
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...
March 6, 2025
Profound Medical Corp. ( TSE:PRN ) shareholders should be happy to see the share price up 11% in the last week. But...
February 22, 2025
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
February 13, 2025
We feel now is a pretty good time to analyse Profound Medical Corp.'s ( TSE:PRN ) business as it appears the company...
January 19, 2025
TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
January 13, 2025
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds...
January 8, 2025
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
January 6, 2025
Next page